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Abstract 
Background: Critically ill patients experience metabolic disorders including hypercatabolic state and 
hyperglycaemia and these are associated with poor outcome.  Hyperglycaemia and asymmetric 
dimethylarginine (ADMA) are reported to have significant influences on endothelial dysfunction.  
The aim of the present study was to examine the relationship between plasma asymmetric 
dimethylarginine (ADMA) and related arginine metabolism in patients with critical illness. 
Materials and Methods: Two venous blood samples (EDTA) (104 patients), on admission and follow 
up sample in the last day in ICU (died or discharge sample median 7, IQR 6-8, range 5-15).  Plasma 
ADMA, arginine, homoarginine and symmetrical dimethylarginine (SDMA) were measured by high-
performance liquid chromatography (HPLC). 
Result: ADMA (p<0.01) and SDMA (p<0.05) were elevated and homoarginine was decreased (p<0.05) 
in non-survivors and were directly associated with predicted mortality rate (p<0.05 and p<0.001), 
SOFA (p<0.05, p<0.001), ICU stay (p<0.05, p<0.001) and mortality (p<0.01, p<0.05).  ADMA was 
directly associated with SDMA (p<0.001), albumin (p<0.05), ICU stay and mortality (p<0.01).  SDMA 
was directly associated with creatinine (p<0.001) and APACHE II score (p<0.001).  In the follow up 
measurements there was a significant decrease in SOFA score (p<0.01), homoarginine (p<0.01), ALT 
(p<0.01), Lab-Glucose (p<0.01), and albumin (p<0.01).  In contrast, there was an increase in arginine 
((p<0.01), ADMA (p<0.01), ADMA:SDMA ratio (p<0.01), and the norepinephrine administration 
(p<0.01). 
Conclusion: In the present longitudinal study ADMA metabolism was altered in patients with critical 
illness and was associated with disease severity and mortality. 
Key words: Homoarginine; arginine; asymmetric dimethylarginine; symmetrical dimethylarginine; 
critical illness. 
 
Key messages: 
1. The significant elevation of ADMA and SDMA in patients with critical illness were directly 
associated with disease severity and mortality. 
2. Plasma homoarginine concentrations were significantly inversely associated with C-reactive 
protein suggesting an effect of inflammation on homoarginine synthesis and/or metabolism. 
3. Plasma homoarginine concentrations were lower in patients with critical illness and were 
also associated with disease severity and mortality. 
 
Introduction  
Patients with critical illness are often hypercatabolic and hyperglycaemic, and these 
metabolic disorders have been shown to have a significant influence on patient outcome [1;2].  
Furthermore, several studies have reported a beneficial effect of controlling hyperglycaemia on 
morbidity and mortality [1;3].  However, the mechanisms by which these beneficial effects are 
brought about remain unclear.  One possible mechanism is the amelioration of endothelial 
dysfunction related to endogenous nitric oxide synthase (NOS) inhibitors [1;4;5]. 
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Endothelial dysfunction has been reported in association with insulin resistance and 
increased concentrations of the NOS inhibitor asymmetric dimethylarginine (ADMA) which may lead 
to a reduction in the bioavailability of nitric oxide (NO) (Figure 1) [6;7].  ADMA has been implicated 
in the endothelial dysfunction accompanying a broad range of clinical disorders such as obesity, 
cardiovascular disease, chronic renal failure, diabetes and hypertension [7-9].  Indeed, a significant 
increase in plasma ADMA concentration has been reported in individuals with impaired glucose 
tolerance [10], diabetes [11] and in the overweight, in whom weight loss was associated with a 
reduction in ADMA and improved markers of insulin sensitivity [10].  It is of interest that, in patients 
with acute illness, increased ADMA concentration has been associated with increased mortality and 
several studies have reported ADMA concentration as an independent risk factor for adverse 
outcomes in patients with critical illness.  For example, in the intensive care unit (ICU) and in severe 
sepsis [1;12-14] and in patients presenting to the emergency department [15].  Siroen reported that 
there was a significant reduction in ADMA concentrations in critically ill patients who received 
intensive insulin treatments compared with patients who were treated conventionally [1].  This 
reduction was associated with a significant improvement in mortality [1;4].  In the critically ill 
patients higher concentrations of ADMA have been associated with increased mortality [10].  
Furthermore improved outcomes have been reported with intensive insulin therapy, with 
amelioration of high ADMA concentrations a possible mechanism for this beneficial effect [1;4], 
possibly through preservation of dimethylaminohydrolase (DDAH) activity, the key enzyme involved 
in ADMA degradation.  Moreover, insulin may decrease the degradation of arginine and thereby 
reduce the production of ADMA [16].  In contrast, however, Iapichino (2008) reported that intensive 
insulin treatments, while achieving tight glucose control, did not reduce ADMA levels in patients 
with septic shock who were fed with no more than 25 kCal/kg per day [17]. 
It has been reported during acute inflammatory response of elective surgery plasma ADMA 
concentration decreases rapidly in the first 48 hours [18].  It has also been shown that inflammatory 
markers, such as interleukin-6 (IL-6), C-reactive protein (CRP) and tumour necrosis factor α are 
inversely associated with ADMA concentrations and the ADMA:SDMA ratio, and this has been 
proposed to be the result of increased (DDAH-mediated) catabolism induced by an inflammatory 
response [13]. 
The aim of the present study was to examine the relationships between the concentrations 
of plasma ADMA and related compounds (homoarginine, arginine, SDMA), length of stay and 
mortality in patients with critical illness.  
 
Methods 
Patients and study design 
Patients in the intensive care unit (ICU) of the Royal Infirmary, Glasgow who were ≥ 18 years 
old, and had evidence of the systemic inflammatory response syndrome as per 1992 consensus 
criteria [19, 20] were studied.  There were no other exclusion criteria.  The study was approved by 
the ethics committees of the North Glasgow NHS Trust and Multicentre Research Ethics Committee 
(MREC) Scotland.  Where patients were unable to give signed informed consent, consent was 
obtained from the patients’ next of kin or welfare guardian in accordance with the requirements of 
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the Adults with Incapacity Scotland (2000) Act. 
Blood samples for population references values were obtained from laboratory staff, from 
local health centres and from people attending a cardiovascular risk clinic.  None of the subjects 
were taking any vitamin supplements or had evidence of a systemic inflammatory response (serum 
C-reactive protein <10 mg/ l). 
Data collection. 
Baseline demographics including age, ICU admission cause, and ICU length of stay were 
extracted from ICU computer using Carevue programme.  Such data was collected as part of routine 
clinical care including laboratory blood glucose, C-reactive protein (CRP), white cell count, albumin, 
creatinine, alanine aminotransferase (ALT) and liver function tests. Drugs and their dosages that may 
have influenced blood glucose were also recorded such as insulin, epinephrine, norepinephrine, 
dobutamine and hydrocortisone.  APACHE II score and predicted hospital mortality and SOFA scores 
were recorded. 
 
ICU insulin protocol  
The blood glucose concentration were targeted at 4.4-6.9 mmol/l (80-124 mg/dl) using a 
standardised insulin infusion protocol using insulin infusion with a concentration of 50 units of 
insulin in 50 ml 0.9% saline. 
There were several enteral feeding preparations used in the ICU such as Jevity (1 Kcal/ml), 
Jevity Plus (1.2 Kcal/ml), Jevity 1.5 (1.5 Kcal/ml) and Osmolite (1 Kcal/ml), Osmolite Plus (1.2 
Kcal/ml), Peptisorb (1 Kcal/ml), Perative (1.31 Kcal/ml) and Nepro (2 Kcal/ml).  Patients routinely 
received 2L of one of these preparations per day, amounting to an intake of 2000-2500 calories per 
day. 
 
Analytical methods  
Collection and preparation of blood samples. 
Venous blood samples (EDTA) were withdrawn on admission (day 1) as well as a  follow up 
sample on the last day of the ICU admission whether the patient died or was discharged (median 7, 
IQR 6-8, range 5-15 days) for the analysis of plasma ADMA, arginine, homoarginine and SDMA.  
Blood samples were centrifuged (500 g, 10 minutes), the plasma removed and stored at -70°C until 
analysis.  Blood samples that formed part of patients’ clinical care were handled in the usual way 
according to established standard operating procedures in the hospital biochemistry laboratory. 
 
Laboratory analysis 
ADMA, arginine, homoarginine and SDMA were measured using isocratic high performance 
liquid chromatography (HPLC) with fluorescence detection as previously described [21].  The 
coefficients of variation (CV) were approximately 3% for the analytes.  Reference values for the 
studied analytes were derived from 86 healthy people [21].  In the present study the control group 
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was not age and sex matched to the ICU patients rather they were to provide a “normal” reference 
range for the analytes measured in the patients with critical illness. 
Blood glucose, CRP, white cell count, albumin, creatinine and alanine aminotransferase (ALT) 
were measured in accordance with the manufacturer’s instructions on an automated analyzer 
(Architect; Abbott Diagnostics, Abbott Park, Chicago, IL) in the routine accredited biochemistry 
laboratory (Clinical Pathology Accreditation UK). For CRP, the limit of detection was 0.5 mg/L.  The 
interassay CV was < 5 % over the sample concentration range for all of the analytes measured. 
 
Statistical analysis 
As the data was not normally distributed it was presented as median (median, IQR) and non 
parametric testing used as appropriate.  The relationship between patient characteristics and plasma 
arginine, homoarginine ADMA and SDMA concentrations were carried out with the use of the Mann-
Whitney U test.  Correlations between variables in the control and critically-ill groups were carried 
out using the Spearman rank correlation.  Data from different time points in the patient groups were 
tested for statistical significance with the use of the Wilcoxon signed rank test.  Due to the number 
of unpaired and paired statistical comparisons carried out a P value of <0.01 was considered to be 
significant.  With reference to ICU mortality data were analysed by univariate binary logistic 
regression analysis and only variables at the P<0.05 significance levels were included in multivariate 
analysis.  Analysis was performed with the use of SPSS software (version 19; SPSS Inc., Chicago, IL). 
 
Results 
In total, one hundred and four adult patients with critical illness (medical n=44, surgical 
n=60) admitted to Glasgow Royal Infirmary ICU in the period between September 2006 to March 
2008 were studied.  The characteristics of the patients with critical illness on admission are shown in 
Table 1.  The majority of patients were male (69%) and had median age of 61 years.  The median 
APACHE II score was 21, predicted hospital mortality rate was 39% and SOFA score was 7.  All 
patients had sepsis and in particular, 10 and 5 patients were treated for severe sepsis and septic 
shock respectively.  Compared with controls (n=86), patients with critical illness had lower median 
arginine and homoarginine concentrations and higher ADMA and SDMA concentrations (all p< 
0.001).  Also, critically ill patients had lower ADMA: SDMA and arginine: ADMA ratios and higher 
total dimethylarginine (sum of ADMA and SDMA) concentrations (both p< 0.001). 
The relationship between patient characteristics, plasma ADMA concentrations, other 
parameters and ICU death is shown in Table 2.  Non-survivors had significantly higher SOFA scores (p 
< 0.001), higher ADMA, SDMA and total dimethylarginine concentrations (all p < 0.05), lower 
homoarginine concentrations (p < 0.028) and lower albumin concentrations (p < 0.017).  They also 
had a longer ICU length of stay (p < 0.001). 
Univariate and multivariate binary logistic regression analysis of clinical characteristics and 
dimethylarginine concentrations on admission to ICU and ICU death in critically ill patients is shown 
in Table 3.  On univariate binary logistic regression analysis of the significant parameters identified in 
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comparison of survivors and non-survivors, only SOFA scores (p <0.01), ICU length of stay (p<0.01), 
homoarginine (p<0.05), ADMA (p< 0.01), ADMA+SDMA (p<0.05) and daily fluid balance were 
significantly associated with ICU mortality.  On multivariate binary logistic regression analysis of 
these significant parameters, only SOFA score (p <0.01) was independently associated with ICU 
mortality.  When SOFA score was removed from the multivariate analysis only ADMA (OR= 23.7, 
p<0.01) and ICU length of stay (OR= 1.04, p< 0.01) were independently associated with ICU 
mortality.  
Of the 104 patients who were admitted into the ICU, 33 patients had a second blood sample 
measurement of plasma ADMA concentrations (Table 4) prior to discharge (n=17) or death (n=16).  
The remaining patients did not have a blood sample due to discharge (n = 61) or death (n = 10).  The 
former patients spent longer in ICU (median 16 days) than the latter patients (median 3 days) and 
therefore were more likely to have a second blood sample.  The median time between admission 
and the last sample was 7 (range 5-15, IQR 6-8) days.  There was a significant decrease in SOFA score 
(p < 0.02), arginine (p<0.008), homoarginine (p<0.001), ALT (p < 0.012), Lab-Glucose (p<0.012), and 
albumin (p<0.012). There was a significant increase in ADMA (p<0.009), ADMA: SDMA ratio (p< 
0.003), and the administration of norepinephrine (p< 0.017). 
 
Discussion 
Plasma dimethylarginines, especially ADMA, have been previously reported to be associated 
with mortality in critically ill patients, and have been speculated to be a cause of endothelial 
dysfunction and multiple organ failure in this patient group [1;13;14;22].  In the present study it was 
shown that plasma concentrations of ADMA and SDMA were significantly higher in critically ill 
patients compared with healthy controls and that both were significantly associated with disease 
severity and mortality.  The strength of association between ADMA and mortality was striking (odds 
ratio ~ 30 and was directly associated with organ dysfunction (SOFA), most closely associated with 
mortality [13]. When SOFA scores were removed from the analysis, the admission ADMA was 
independently associated with ICU mortality. This association supports the hypothesis that ADMA 
metabolism may play a causative role in endothelial dysfunction through impairment of NOS activity.  
However, further studies of ADMA metabolism are warranted in patients with critical illness. 
Homoarginine is an amino acid largely generated from lysine and may promote endothelial 
function as a substrate for NO synthesis [23], although it may be present at too low a concentration 
for this to be important, given the relative concentration of arginine is about 30 times greater [21].  
A potentially more important role that has received some attention is in the inhibition of the enzyme 
arginase with consequent preservation of arginine for NOS [24].  Indeed, low homoarginine 
concentrations have been recently shown to be associated with mortality and cardiovascular events 
[25].  Furthermore, increased homoarginine concentrations during normal pregnancy are associated 
with increases in brachial artery diameter and flow-mediated dilatation [26].  In the present study, 
homoarginine was positively associated with arginine (rs = 0.641, p<0.001), consistent with the 
above concept.  Indeed, homoarginine was significantly inversely associated with C-reactive protein 
(rs= -0.349, p= 0.001) suggesting an effect of inflammation on homoarginine synthesis and/or 
metabolism. 
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In the present study SDMA was also associated with increased mortality.  However, there 
was a strong association between SDMA and creatinine concentrations on admission (n= 104, rs= 
0.62, p<0.001) and on follow-up (n= 60, rs= 0.76, p<0.001) and therefore plasma SDMA 
concentrations, in the main, reflect renal function, which is perhaps not surprising given that its 
main route elimination is renal.  It has previously been speculated that by competing with arginine 
uptake at cationic amino acid transporters (CAT) SDMA can impair the delivery of the substrate 
arginine to NOS [27].  However, it has not been established whether the concentrations 
encountered in vivo are sufficient to have a significant effect.  Therefore, it may be that the 
association of SDMA with mortality simply reflects the effect of renal impairment. 
ADMA and SDMA are generated by the methylation of arginine residues in proteins by type 
1 protein arginine methyltransferases (type 1 PRMTs) and from type 2 protein arginine methyl 
transferases (type 2 PRMTs) respectively.  Daily production of ADMA is approximately 300 µmol with 
about 10% of this amount excreted unchanged into the urine. The majority is metabolized by 
dimethylarginine dimethylaminohydrolase (DDAH) to citrulline and dimethylamine.  In contrast, 
SDMA is mainly excreted unchanged in urine and is increasingly being regarded as a sensitive marker 
of renal function [11;28]. 
In the present study the ADMA: SDMA ratio was significantly lower in critically-ill patients 
compared with controls.  The ADMA: SDMA ratio has previously been shown to be reduced in 
patients with acute infections, severe sepsis, post-operatively and in rats following 
lipopolysaccharide administration; it has been speculated that the reduction in ratio reflects an 
inflammation-induced increase in ADMA clearance through DDAH activity [13;29-31].  However, in 
no such study has DDAH activity in vivo been assessed, and therefore no conclusion can be reached 
about this at the present time; indeed in the present study there was no direct association between 
CRP and ADMA concentration.  Inflammatory cytokines have been shown to both increase and 
decrease DDAH activity in different models [32;33], but the net effect in vivo, taking into account the 
confounding effects of oxidative stress and NO itself, is unclear. 
A novel aspect of the present study was the longitudinal measurement of ADMA 
metabolism.  In the present study approximately one third of patients had follow-up analysis.  The 
mortality was greater in those patients with a follow-up sample compared to those who did not 
(48% vs 25%).  Moreover, length of ICU stay was greater in this group (median 16 days vs 3 days).  
Therefore, this subsample is likely to represent a group of sicker patients.  Nevertheless, the ADMA 
and arginine concentrations increased on subsequent sampling whereas SOFA scores, homoarginine 
and glucose concentrations fell. In contrast, C-reactive protein concentrations were not altered. 
Therefore, from these results and from the foregoing discussion it is clear ADMA metabolism in the 
patient with critical illness is complex.  However, a similar pattern has been reported in patients 
undergoing elective surgery who had a significant inflammatory response, although in those patients 
this was following a significant reduction in ADMA concentration from baseline [18].  In these 
patients there was no change in SDMA concentrations, indicating differential handling of the 
dimethylarginines.  However, there was no clear evidence of increased ADMA metabolism, and it 
may be have been that ADMA transport via CATs was the more important factor [18;34].  This is an 
area which is worthy of further study in critical illness, as it is becoming clear that the plasma 
concentrations may not reflect the pathophysiologically important tissue concentrations, which even 
in health are up to 10 – 20 times that found in plasma [2;32]. 
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There are two distinct isoforms of DDAH.  DDAH-1 is widely expressed, particularly in tissues 
such as liver, renal cortex, lung and immune tissues and cells.  There are large arterio-venous 
gradients across organs such as the liver and kidney, and DDAH-1 has been described as the 
“guardian” of circulating ADMA concentration [35].  In contrast, DDAH-2 is mainly found in tissues 
which express endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) 
such as endothelium and smooth muscle cells of cardiovascular system  [36;37].  As such, DDAH-2 
appear to be more involved in the regulation of local endothelial responses [35].  Consequently, 
ADMA concentrations in plasma are regulated within fairly narrow limits in health, and it is clear that 
DDAH-mediated metabolism is the critical step in this regulation [37;38]. 
The activity of dimethylaminohydrolase (DDAH) is highly dependent on a cysteine residue at 
its catalytic site.  This is susceptible to oxidation as a consequence of oxidative stress and may 
provide a mechanism that results in increased ADMA concentration and reduced NO formation [37].  
This has been observed with hyperglycaemia and hyperhomocystinaemia [37].  Therefore, 
interaction between dimethylaminohydrolase (DDAH), ADMA and NOS may present a common 
pathway of several risk factors affecting the vascular endothelium. 
Indeed, a recent study in critically ill rabbits showed that tissue DDAH activity was a stronger 
determinant of plasma than tissue ADMA concentration, suggesting that CAT-mediated exchange of 
ADMA between compartments might be even more important than changes in DDAH activity itself 
[39].  Previous work has documented increased fractional excretion of ADMA by the liver during 
endotoxaemia [30], but, again, this does not differentiate between an increase in CAT-mediated 
uptake and a true increase in DDAH activity itself. In this regard, it has also been shown that 
methylarginine uptake into endothelial cells and macrophages increases with cytokine stimulation 
[34].  With current limitations in knowledge, caution should be exercised when interpreting the 
ADMA: SDMA ratio that might not be useful as a simple surrogate marker of DDAH activity for these 
reasons. 
Limitations of the present study were principally that it was a single centre study and there 
was no validation cohort.  The cohort was a mix of surgical and medical patients and there was 
considerable variation in the severity of illness.  Furthermore, there were significant attrition of 
patients on follow up and this limits interpretation of the data and the conclusions that can be 
reached. 
In summary, plasma ADMA and SDMA concentrations were higher in patients with critical 
illness and were associated with disease severity and mortality.  In contrast, plasma homoarginine 
concentrations were lower in patients with critical illness and were also associated with disease 
severity and mortality.  These results suggest that ADMA metabolism is perturbed with likely knock 
on effects on NOS and endothelial function.  There is a need for further work on in vivo DDAH 
activity in critical illness and the effect of critical illness on the CAT-mediated exchange of ADMA 
between intra and extra-cellular compartments.
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ICU: Intensive Care Unit. 
Lab-Glucose: Laboratory Glucose. 
CRP: C-reactive protein. 
ALT: aminotransferase. 
NOS: nitric oxide synthase. 
APACHE II: Acute physiology and Chronic Health Evaluation II score. 
SOFA: Sequential Organ Failure Assessment. 
HPLC: high-performance liquid chromatography. 
CV: coefficients of variation. 
ADMA: Asymmetrical Dimethylarginine. 
SDMA: Symmetrical Dimethylarginine. 
DDAH: dimethylarginine dimethylaminohydrolase. 
CAT:  cationic amino acid transporters. 
IQR: interquartile range 
 
Figure 1:  Interactions between oxidative stress, dimethylarginine dimethylaminohydrolase (DDAH), 
asymmetric dimethylarginine (ADMA) and nitric oxide synthase (NOS). SDMA, symmetric 
dimethylarginine; PRMTs, protein arginine methyltransferases; TNF-a, tumour necrosis factor-a 
(Blackwell, 2010) 
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Table 1.  Admission characteristics and arginine, homoarginine, ADMA and SDMA 
concentrations in normal subjects and critically-ill patients (n=104).  
 Reference Intervals 
(Control) (n=86) 
Patients with critical 
illness (n=104) 
P-value* 
Age (Year) 43 (20-65) 61 (47-71)  
Gender (Male/Female) (%) 44 (51)/ 42 (49) 72 (69)/32 (31)  
Admission cause (Surgical/Medical) (%)  60 (58)/44 (42)  
APACHE II  21 (17-27)  
Predicted mortality rate (%)  38.9 (17.6-60.4)  
SOFA score  7.0  (4.0-9.0)  
Severe sepsis/septic shock (%)  10 (10)/5 (5)  
    
Arginine (µmol L-1)  65.7 (48.8-79.9) 18.4 (12.9-29.1) <0.001 
Homoarginine (µmol L-1)  1.90 (1.38-2.49) 0.58 (0.32-1.18) <0.001 
ADMA(µmol L-1)  0.45 (0.41-0.52) 0.54 (0.41-0.64) <0.001 
SDMA (µmol L-1)  0.38 (0.34-0.43) 0.75 (0.52-1.15) <0.001 
ADMA/SDMA ratio 1.20 (1.10-1.36) 0.73 (0.43-1.02) <0.001 
Arginine/ADMA ratio 125.7 (101.0-171.5) 36.7 (26.0-56.6) <0.001 
Total dimethylarginine (µmol L-1) 0.82 (0.76-0.88) 1.2 (1.0-1.83) <0.001 
    
Creatinine (umol/L)§ 68-118  117 (78-171)  
Total Bilirubin (umol/l) § 5.1–17.0 10.5 (7.0-21.0)  
ALT (U/L) § 10-40  37 (18-115)  
Lab-Glucose (mmol/l) § 3.5-5.5 6.4 (5.5-8.1)  
C-reactive protein (mg/l) § <10 119 (41-216)  
White cell count (109/L) § 4-11 x109 11.4 (7.9-18.5)  
Albumin (g/l) § 35-55 16 (12-21)  
Daily fluid balance (ml)  1034 (393-2343)  
    
Insulin (U hour -1) ‡  0.9 (0.0-9.3)  
Norepinephrine (mg hour-1) ‡  0.5 (0.0-6.0)  
Epinephrine (mg hour-1) ‡  0.1 (0.0-2.7)  
Dobutamine (mg hour-1) ‡  2.5 (0.0-76.4)  
Hydrocortisone (mg hour-1) ‡  1.9  (0.0-16.0)  
    
ICU length of stay (Days)  5.1 (2.0-13.6)  
ICU death No/Yes   78 (75%)/26 (25%)  
    
Median (interquartile range, IQR), § reference interval, ‡ Mean (range), * Mann-Whitney U. 
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Table 2  Admission patient characteristics and measurements between survivors and non-
survivors (n=104).  
 
Median (interquartile range, IQR), ‡ Mean (range), * Mann-Whitney U. 
 
Admission Survivors 
(n=78) 
Admission Non-survivors 
(n=26) 
P-value*
Age (Year) 60 (43-69) 67 (48-74) 0.175
Gender (Male/Female) (%) 55 (71)/23 (29) 17/9 0.625
Admission cause (Surgical/Medical) (%) 45 (58)/33 (42) 15/11 1.000
APACHE II 21 (16-26) 24 (18-31) 0.174
Predicted mortality rate (%) 35.3 (14.1-57.3) 45.6 (23.3-73.8) 0.061
SOFA score 5 (4-8) 8 (7-11) 0.001
Severe sepsis/septic shock (%) 7 (9)/5 (6) 3 (12)/0 (0)  
    
Arginine (µmol L-1) 17.5 (12.1-29.0) 19.6 (17.3-34.9) 0.281
Homoarginine (µmol L-1)  0.70 (0.35-1.30) 0.50 (0.26-0.77) 0.028
ADMA(µmol L-1) 0.49 (0.38-0.62) 0.59 (0.52-0.90) 0.003
SDMA (µmol L-1) 0.69 (0.50-1.10) 0.94 (0.57-1.72) 0.047
ADMA/SDMA ratio 0.72 (0.43-1.02) 0.79 (0.37-1.05) 0.866
Arginine/ADMA ratio 38.5 (25.7-59.2) 33.3 (26.0-49.2) 0.218
Total dimethylarginine (µmol L-1) 1.2 (0.92-1.68) 1.7 (1.2-2.5) 0.008
    
eGFR   >30/ <30 10 (0-35) 11 (0-28) 0.747
Creatinine (umol/L) 115 (73-169) 118 (79-249) 0.605
Total Bilirubin (µmol/l) 10.5 (8-20) 10.5 (7-28) 0.980
ALT 38.5 (19-129) 37 (15-115) 0.556
Lab-Glucose (mmol/l) 6.4 (5.5-8.1) 6.8 (5.4-9.2) 0.642
C-reactive protein (mg/l)  108 (40-218) 125 (42-169) 0.870
White cell count (109/L) 10.8 (7.6-16.9) 16.3 (7.9-20.0) 0.223
Albumin (g/l) 17 (13-23) 13 (10-19) 0.017
Daily fluid balance (ml) 1006 (393-2166) 4793 (-7-5113) 0.167
    
Insulin (U hour -1) ‡ 0.9 (0.0-9.3) 0.7 (0.0-4.8) 0.874
Norepinephrine (mg hour-1) ‡ 0.4 (0.0-2.5) 0.8 (0.0-6.0) 0.292
Epinephrine (mg hour-1) ‡ 0.1 (0.0-2.7) 0.1 (0.0-1.0) 0.894
Dobutamine (mg hour-1) ‡ 2.4 (0.0-76.4) 2.7 (0.0-50.0) 0.431
Hydrocortisone (mg hour-1) ‡ 2.2 (0.0-16.0) 1.2 (0.0-8.0) 0.276
    
ICU length of stay (Days) 3 (1-10) 11.6 (6-19) <0.001
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Table 3.  The relationship between clinical characteristics and ADMA on admission to ICU mortality 
in patients with critical illness.  Univariate and multivariate binary logistic regression analysis. 
 Univariate analysis 
OR (95%CI) 
P-value Multivariate analysis 
OR (95%CI) 
P-value 
Age (years) 1.02 (0.99-1.05) 0.292   
Sex (male/female) 1.27 (0.49-3.25) 0.624   
Patients (medical/surgical) 1.00 (0.41-2.46) 1.000   
APACHE II score 1.05 (0.99-1.12) 0.138   
Predicted mortality rate (%) 1.02 (0.99-1.03) 0.081   
SOFA score 1.34 (1.12-1.61) 0.002 1.053 (1.104-2.120) 0.011 
ICU length of stay (days) 1.05 (1.01-1.09) 0.007 0.951 (0.097-9.323) 0.965 
Arginine (µmol L-1) 1.02 (0.99-1.05) 0.241   
Homoarginine (µmol L-1) 0.39 (0.15-0.99) 0.048 0.545 (0.105-2.837) 0.471 
ADMA(µmol L-1) 31.31 (3.34-293.18) 0.003 0.793 (0.003-218.189) 0.936 
SDMA (µmol L-1) 1.54 (0.90-2.64) 0.118   
ADMA/SDMA ratio 1.10 (0.30-4.06) 0.887   
Arginine/ADMA ratio 0.99 (0.97-1.01) 0.243   
ADMA+SDMA 1.66 (1.02-2.70) 0.041 2.653 (0.090-78.137 0.572 
eGFR   >30/ <30 0.99 (0.97-1.02) 0.771   
Creatinine umol/L 1.00 (0.99-1.00) 0.721   
Bilirubin (umol/l) 1.00 (0.99-1.01) 0.858   
ALT (u/l) 1.00 (1.00-1.00) 0.661   
Lab-Glucose mmol/l 1.05 (0.94-1.16) 0.413   
C-reactive protein (mg/l) 1.00 (0.99-1.01) 0.665   
Albumin (g/l) 0.92 (0.85- 1.00) 0.063   
Daily fluid balance (ml) 1.00 (1.00-1.00) 0.020 1.000(1.000-1.001) 0.427  
Insulin (U hour -1) 0.93 (0.70-1.24) 0.623   
Norepinephrine (mg hour-1) 1.51 (0.95-2.40) 0.079   
Epinephrine (mg hour-1) 0.89 (0.25-3.23) 0.864   
Dobutamine (mg hour-1) 1.00 (0.96-1.05) 0.896   
Hydrocortisone (mg hour-1) 0.92 (0.800-1.06) 0.263   
OR, odds ratio 
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Table 4. The relationship between patient characteristics and plasma arginine, homoarginine, 
ADMA, and SDMA concentrations in critically-ill patients on admission and (follow-up) last 
sample median day 7 (range 5-15) (IQR 6-8) 
 Critically-ill patients 
Admission (n=33) 
Critically-ill patients 
Follow-up (n=33)  
P-value* 
Age (yr) 64 (51-71)   
Sex (M/F) (%) 23 (70%) /10 (30%)   
Medical/ Surgical (%) 19 (58%) /14 (42%)   
APACHE II score 24 (18-29)   
Predicted mortality (%) 46.0 (21.8-71.9)   
SOFA score 8 (6-10) 6 (4-8) 0.002 
Severe sepsis/septic shock 2/1   
    
Arginine (µmol L-1) 19.1 (12.8-31.8) 24.3 (21.5-35.6) 0.008 
Homoarginine (µmol L-1) 0.56 (0.35-1.22) 0.33 (0.12-0.42) <0.001 
ADMA(µmol L-1) 0.60 (0.50-0.84) 0.71 (0.57-1.04) 0.009 
SDMA (µmol L-1) 0.87 (0.53-1.44) 0.94 (0.51-1.49) 0.829 
ADMA/SDMA ratio 0.75 (0.43-1.04) 0.89 (0.57-1.25) 0.003 
Arginine/ADMA ratio 31.2 (16.3-44.2) 40.0 (27.0-46.3) 0.236 
ADMA+SDMA 1.5 (1.04-2.44) 1.6 (1.16-2.52) 0.936 
    
eGFR   >30/ <30 20.0 (0.0-33.5) 17.0 (0.0-30.0) 0.604 
Creatinine (umol/L) 126 (93-204) 167 (91-278) 0.626 
Bilirubin (umol/l) 11 (7-20) 11 (6-27) 0.350 
ALT (u/l) 57 (1-171) 42 (21-96) 0.012 
Lab-Glucose mmol/l 7.4 (5.9-10.5) 6.2 (5.2-7.0) 0.012 
C-reactive protein (mg/ l) 72 (13-156) 131 (56-173) 0.597 
White cell count (109/L) 10.6 (7.4-18) 12.0 (9.2-20.8) 0.320 
Albumin (g/ l) 15 (10-21) 13 (11-16) 0.012 
Daily fluid balance (ml) 469 (-21-2000) 1491 (-275-2148) 0.778 
    
Insulin (U hour -1) ‡ 1.0 (0.0-9.3) 2.1 (0.0-10.9) 0.148 
Norepinephrine (mg hour-1) ‡ 0.4 (0.0-4.0) 0.5 (0.0-4.4) 0.017 
Epinephrine (mg hour-1) ‡ 0.1 (0.0-2.7) 0.07 (0.0-1.6) 0.028 
Dobutamine (mg hour-1) ‡ 3.9 (0.0-76.4) 4.5 (0.0-117) 0.028 
Hydrocortisone (mg hour-1) ‡ 2.1 (0.0-16.0) 2.4 (0.0-16.0) 0.058 
    
ICU length of stay (days) 16 (11-27)   
ICU death (no/ yes) (%) 17 (52)/16 (48)   
 
Median (interquartile range, IQR), ‡ Mean (range), * Wilcoxon signed rank test. 
